tiprankstipranks
UCB SA (UCBJY)
OTHER OTC:UCBJY
Holding UCBJY?
Track your performance easily

UCB SA (UCBJY) Stock Price & Analysis

15 Followers

UCBJY Stock Chart & Stats


Financials

Annual

Options Prices

Currently, No data available
---

Ownership Overview

0.00%0.00%<0.01%100.00%
0.00%
Insiders
<0.01% Other Institutional Investors
100.00% Public Companies and
Individual Investors

UCBJY FAQ

What was UCB SA’s price range in the past 12 months?
UCB SA lowest stock price was $35.09 and its highest was $91.47 in the past 12 months.
    What is UCB SA’s market cap?
    Currently, no data Available
    When is UCB SA’s upcoming earnings report date?
    UCB SA’s upcoming earnings report date is Feb 27, 2025 which is in 96 days.
      How were UCB SA’s earnings last quarter?
      UCB SA released its earnings results on Jul 25, 2024. The company reported $1.134 earnings per share for the quarter, beating the consensus estimate of $0.953 by $0.181.
        Is UCB SA overvalued?
        According to Wall Street analysts UCB SA’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does UCB SA pay dividends?
          UCB SA pays a Annually dividend of $0.46 which represents an annual dividend yield of 0.51%. See more information on UCB SA dividends here
            What is UCB SA’s EPS estimate?
            UCB SA’s EPS estimate is $1.31.
              How many shares outstanding does UCB SA have?
              UCB SA has 389,012,000 shares outstanding.
                What happened to UCB SA’s price movement after its last earnings report?
                UCB SA reported an EPS of $1.134 in its last earnings report, beating expectations of $0.953. Following the earnings report the stock price went up 2.641%.
                  Which hedge fund is a major shareholder of UCB SA?
                  Currently, no hedge funds are holding shares in UCBJY
                  ---

                  UCB SA Stock Smart Score

                  10
                  Unlock Smart Score
                  1
                  2
                  3
                  4
                  5
                  6
                  7
                  8
                  9
                  10

                  Technicals

                  SMA
                  Positive
                  20 days / 200 days
                  Momentum
                  100.86%
                  12-Months-Change

                  Fundamentals

                  Return on Equity
                  2.67%
                  Trailing 12-Months
                  Asset Growth
                  -0.19%
                  Trailing 12-Months

                  Company Description

                  UCB SA

                  UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, both of which have lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Evenity (osteoporosis), and Nayzilam (cluster seizures).
                  ---

                  UCBJY Company Deck

                  ---

                  UCBJY Earnings Call

                  Q2 2024
                  0:00 / 0:00
                  ---
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  AbbVie
                  Bristol-Myers Squibb
                  GlaxoSmithKline
                  Pfizer
                  Popular Stocks
                  ---
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis